English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe Oncotarget data shed new light on the biochemical mechanisms behind ibuprofen’s action on alternative spliced RAC1B and may support its use in personalized approaches to CRC therapy or chemoprevention regimens.
Tag: prostate cancer
White button mushrooms could slow progression of prostate cancer
The chemicals present in white button mushrooms may slow the progression of prostate cancer, according to a mouse study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
White button mushrooms could slow progression of prostate cancer
Mouse study suggests mushrooms may suppress androgen receptor activity
LSU Veterinary School receives $11M COBRE grant for a pre-clinical cancer research center
The Louisiana State University School of Veterinary Medicine, or LSU SVM, has received an $11 million grant to establish a Center of Biomedical Research Excellence, or COBRE. The COBRE funds will create the Center for Pre-Clinical Cancer Research, or Cancer…
Oncotarget: Quantitative proteome profiling stratifies fibroepithelial lesions of the breast
The present Oncotarget work shed light on a brief mechanistic framework of PTs aggressive nature and present potential biomarkers to differentiate overlapping FELs that would be of practical utility in augmenting existing diagnosis and disease management
Research News Tip Sheet: Story Ideas from Johns Hopkins Medicine
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every other Wednesday.
Cancer mutations insight could boost detection and personalize treatments
The understanding of many common cancers could be revolutionized by the discovery that in some cases the disease is partly triggered by large numbers of inherited genetic mutations — previously thought to have little impact on cancer risk
Oncotarget: Genomic and neoantigen evolution in head and neck squamous cell carcinoma
In this Oncotarget study, the authors characterized the mutational and neoantigen burden between primary and first recurrence tumors in 23 patients with HNSCC
Doctors should address reduced sense of taste and smell in cancer patients, Tulane study says
The study is a joint project of the Tulane Department of Psychology and the Tulane Cancer Center.
Oncotarget: A novel isoform of Homeodomain-interacting protein kinase-2
This @Oncotarget study indicates that HIPK2 isoform 3, the main HIPK2 isoform expressed in NSCLC, promotes YAP/TEAD transcriptional activity in NSCLC cells
Oncotarget: Folinic acid in colorectal cancer: Esquire or fellow knight?
Showing a clear clinical benefit for patients, irrespective of RAS mutational status, primitive tumor side and metastases surgery
Oncotarget: MicroRNA-4287 is controlling epithelial-to mesenchymal transition in prostate cancer
miR-4287 has potential diagnostic and therapeutic significance in preventing advanced, metastatic disease
Study finds high tumor mutation burden predicts immunotherapy response in some, but not all, cancers
A high rate of genetic mutations within a tumor, known as high tumor mutation burden, was only useful for predicting immunotherapy responses in a subset of cancer types, suggesting that this may not reliably be used as a universal biomarker.
Henry Ford Cancer Institute aims to increase minority participation in clinical trials
$750,000 grant from Genentech will support collaboration with the Detroit Urban Research Center
Targeted screening for prostate cancer could prevent one in six deaths
Peer-reviewed | modelling | people
New AI approach enables research collaboration while protecting patient privacy
Dr. Corey Arnold and his graduate student, Karthik Sarma, explain how federated learning can enable more powerful AI models while enhancing the protection of patient data
Oncotarget: Estrogen receptor α polymorphism is associated with dementia
“In conclusion, estrogen receptor α PvuII polymorphism is associated with dementia in a Brazilian cohort”
Oncotarget: High-fat ovariectomized mice susceptible to accelerated tumor growth
There is convincing evidence that excess body weight is associated with increased risk for late onset (> 50 years of age) colorectal cancer (CRC)
Oncotarget: Sensitivity testing on ovarian cancer cells isolated from malignant ascites
The aim of this @Oncotarget study is to determine whether tumor cells isolated from ascites of EOC patients can be used to determine chemotherapy sensitivity by using in vitro proliferation assays
Predicting success in therapy with individualized cancer models
In the EU alone, 78,800 men died of prostate cancer last year. While tumors discovered at an early stage can often be completely removed by surgery and radiation therapy, the prospects of successful treatment are reduced if the cancer has…
$1m grant funds research on potential new RX for prostate cancer
New Orleans, LA – The Biomedical Laboratory Research and Development Branch of the Veterans Administration (VA) has awarded Hari Koul, PhD, Professor and Interim Chairman of the Department Biochemistry & Molecular Biology at LSU Health New Orleans School of Medicine,…
NE Ohio initiative to increase prostate cancer screening in African Americans
Supported with three-year, $2.75M grant from Bristol Myers Squibb Foundation
Natural product isolated from sea sponge tested against cancer cells
Scientists from Far Eastern Federal University (FEFU) together with Russian and German colleagues, continue studying antitumor compounds synthesized based on bioactive molecules isolated from a sea sponge. One of them fights cancer cells resistant to standard chemotherapy, and at the…
Oncotarget: Effect of liver fibrosis on survival in patients with intrahepatic cholangiocarcinoma
The @Oncotarget authors aimed to assess the effect of cirrhosis on outcomes in iCCA patients
Oncotarget: Exploiting the metabolic dependencies of the broad amino acid transporter SLC6A14
“Suggesting that combined targeting of SLC6A14 and AMPK can be exploited as a therapeutic approach to starve tumor cells”
Oncotarget: Identification intermediate-risk subgroups in metastatic clear-cell renal cell carcinoma
“Elevated PLT count seems to identify a subgroup of patients with poor outcome in the IMDC intermediate-risk population with ccRCC”
Efficient, systematic genetic analysis helps dissect disease inheritance
Many genetic variants have been found to have a linkage with genetic diseases, but the understanding of their functional roles in causing diseases are still limited. An international research team, including a biomedical scientist from City University of Hong Kong…
Genetic Tool Improves Estimation of Prostate Cancer Risk in Diverse Ethnic/Racial Groups
Scientists at University of California San Diego School of Medicine validated a more inclusive and comprehensive genetic tool, known as a polygenic hazard score (PHS), for predicting age of onset of aggressive prostate cancer.
Oncotarget: MEK is a promising target in the basal subtype of bladder cancer
“The @Oncotarget authors demonstrate that MEK inhibitors are a promising targeted therapy for the basal subtype of bladder cancer, and their data indicate that drug screening of 3D cultures provides an important resource for hypothesis generation”
Oncotarget: MEK inhibitors relevant to SARS-CoV-2 infection
The @Oncotarget authors show a drug class-effect with MEKi to stimulate NK cells, inhibit inflammatory cytokines and block host-factors for SARS-CoV-2 infection leading also to suppression of SARS-CoV-2-S pseudovirus infection of human cells
Targeting MAPK4 emerges as a promising therapy for prostate cancer
The battle against late-stage prostate cancer might have found a potential new strategy to combat this deadly disease. Research led by Baylor College of Medicine reveals in the Journal of Clinical Investigation that the enzyme MAPK4 concertedly activates androgen receptor…
Addressing the biological causes of racial disparities in prostate cancer
African Americans have higher rates of prostate cancer and are more likely to die from the disease than other groups in the United States, likely due to socioeconomic factors, healthcare access problems, and tumor biology. A new review published in…
Surface testing for SARS-CoV2 in hematology/oncology settings reveals negligible detection
Rutgers Cancer Institute of New Jersey research published in ‘Cancer’
Mount Sinai Experts Address the Biological Causes of Racial Disparities in Prostate Cancer
African Americans have higher rates of prostate cancer and are more likely to die from the disease than other groups in the United States, likely due to socioeconomic factors, healthcare access problems, and tumor biology.
Toward a disease-sniffing device that rivals a dog’s nose
Trained dogs can detect cancer and other diseases by smell. A miniaturized detector can analyze trace molecules to mimic the process
Scientists able to see how potential cancer treatment reacts in single cell
In the paper, ‘Tracking Reactions of Asymmetric Organo-Osmium Transfer Hydrogenation Catalysts in Cancer Cells’, published in the journal Angewandte Chemie , researchers from the University of Warwick have, for the first time, used the new 185 m beamline to track…
Model helps predict which patients will benefit most from PSMA PET scan
A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which patients with prostate cancer will benefit most from the use of prostate-specific membrane antigen PET imaging, PSMA PET, a novel imaging technique that recently was approved by the U.S. Food and Drug Administration.
Green tea compound aids tumor-suppressing, DNA-repairing protein
Research offers new lead for cancer drug discovery
Antitumoral effects of LXR activation
Macrophages that boost tumor growth
Genomic Test Helps Estimate Risk of Prostate Cancer Metastasis, Death
A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers.
Mount Sinai Receives $3.8 Million Gift to Launch Mobile MRI Unit to Support Prostate Health in the Black Community
The Milton and Caroll Petrie Department of Urology at Mount Sinai has received a $3.8 million donation from philanthropist Robert F. Smith to launch the Robert F. Smith Mobile MRI Unit in partnership with the Mount Sinai Health System to support prostate health in the Black community.
Study: New Prostate Cancer Test Could Avoid Unnecessary Biopsies
A urine test based on University of Michigan Rogel Cancer Center research could have avoided one third of unnecessary prostate cancer biopsies while failing to detect only a small number of cancers, according to a validation study that included more than 1,500 patients.
Oncotarget: Evaluation of cancer-derived myocardial impairments using a mouse model
‘The established mouse cachexia model can therefore be considered useful for analyzing cancer-derived myocardial damage’
Oncotarget: Melatonin increases overall survival of prostate cancer patients
‘The results of the use of melatonin drugs in palliative treatment of patients with end-stage prostate cancer are shown’
Why Black men’s prostate cancer may be more responsive to immunotherapy
Discovery paves way to precision medicine for prostate cancer in all races
Oncotarget: Combination of copanlisib with cetuximab improves tumor response
“These data support further investigation of PI3K inhibition in HNSCC and suggests gene expression patterns associated with PI3K signaling”
HKBU and CUHK launch Spermine Risk Score for prostate cancer diagnosis
Researchers from Hong Kong Baptist University (HKBU) and the Faculty of Medicine at The Chinese University of Hong Kong (CU Medicine) have jointly developed the Spermine Risk Score which, coupled with the use of a urine test, provides a non-invasive…
Joint radionuclide therapy-immunotherapy approach effective in prostate cancer model
Reston, VA–A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of The Journal of Nuclear Medicine . The results…
Clinical trial: Using MRI for prostate cancer diagnosis equals or beats current standard
Phase III clinical trial of men with a clinical suspicion of prostate cancer finds MRI with targeted biopsies to be more accurate at diagnosis and less intrusive than current standard
Hypoxia, a feature inside solid cancer tumors, reprograms methylation of ribosomal RNAs
Altered epigenetic marks on ribosomal RNAs appear to create a pool of specialized ribosomes that can differentially regulate translation of specific messenger RNA